Mandate

Vinge advises PulPac in conjunction with investment

Vinge has advised PulPac AB in connection with an investment in the aggregate amount of MEUR 31 from strategic partners Aliaxis, Stora Enso, Amcor Ventures and Teseo Capital. Existent owners, including cornerstone investor WPP, have also participated in the equity raise.

PulPac has developed a way to manufacture materials and products similar to plastics including, among other things, packaging, using paper as a raw material instead of plastic, so-called Dry Molded Fiber, in a process which requires far less water than previous methods. The company was founded in 2018, employs approximately 70 people and is based in Gothenburg.

Vinge’s team primarily consisted of Kristian Ford, Sofie Nordgren, Carl Trolle Olsson, Lisa Bourghardt and Karin Gynnerstedt.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026